Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I study of tumor specific potentiated vaccine therapy using cyclophosphamide combined epitope peptide cocktail [cancer vaccines + interleukin 2 agonists] for progressive/relapsed solid tumors(GI[gastro-intestinal]/lung/cervical cancer).

Next Previous
Trial Profile

Phase I study of tumor specific potentiated vaccine therapy using cyclophosphamide combined epitope peptide cocktail [cancer vaccines + interleukin 2 agonists] for progressive/relapsed solid tumors(GI[gastro-intestinal]/lung/cervical cancer).

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 18 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cancer vaccines; Cyclophosphamide; Interleukin 2 stimulants
  • Indications Cervical cancer; Gastrointestinal cancer; Lung cancer
  • Focus Adverse reactions

Most Recent Events

  • 23 Jun 2011 Biomarkers information updated
  • 22 Jun 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
  • 22 Jun 2011 Actual end date (March 2010) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top